Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-770 effect on lung imaging in Cystic Fibrosis
NCT01161537Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2010
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Oct 2010; status: completed.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT01161537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01161537.